WHO ICTRP trial

Protocol Title: The ASCEND Study: A Phase III, Multicenter, Double Blinded…

EUCTR2022-000459-35-FR · EU Clinical Trials Register · Authorised

Key facts

Trial ID EUCTR2022-000459-35-FR
Public title Protocol Title: The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - with a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (Xlinked) or ARCI Ichthyosis in Subjects Aged =6 Years
Scientific title Protocol Title: The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - with a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (Xlinked) or ARCI Ichthyosis in Subjects Aged =6 Years - ASCEND
Primary sponsor Timber Pharmaceuticals, LLC
Registry EU Clinical Trials Register
Recruitment status Authorised
Study type Interventional clinical trial of medicinal product
Phase Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries Canada;Austria;United States;Italy;France;Germany;Spain
Conditions Congenital ichthyosis;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Interventions Product Name: TMB-001 ointment 0.05% Product Code: TMB-001 Pharmaceutical Form: Ointment Pharmaceutical form of the placebo: Ointment Route of administration of the placebo: Cutaneous use
Registration date Jun 13, 2022
Target size 142
Secondary IDs TMB01-301;2022-000459-35-DE
Registry page clinicaltrialsregister.eu

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations